LivaNova PLC is a global medical technology company built on 50+ years of experience and a Vision to change the trajectory of lives for a new day. Our Mission is to create ingenious medical solutions that ignite patient turnarounds.
At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach.
LivaNova is listed on the Nasdaq stock exchange under the ticker symbol “LIVN.” LivaNova has approximately 3,000 employees worldwide. Our registered office is in the United Kingdom and we maintain a presence in more than 100 countries.
As a worldwide leader in cardiopulmonary and neuromodulation, we don’t just treat conditions—we aspire to alter the course of lives. So from patients seeking answers to impossible situations to clinicians striving to do their best work to employees finding a place where they can change the world—
Welcome to LivaNova. Welcome to your new life.
*Best Place to Work in Healthcare*
Founded by Dr. Craig Walker in 1983, Cardiovascular Institute of the South (CIS) is a world-leader in preventing, detecting, and treating cardiovascular and peripheral vascular disease. CIS offers a comprehensive heart and vascular program with expert physicians trained in many specialties, including internal medicine, nuclear cardiology, electrophysiology, lipid management, coronary artery disease, peripheral vascular disease, valve disease, and interventional cardiovascular procedures. CIS has earned international acclaim as a pioneer of research, development and education, as well as an innovator in the treatment of peripheral vascular disease. With a dedicated team of more than 900 team members, CIS provides comprehensive cardiovascular care at 21 locations across Louisiana and Mississippi, eight of which offer telemedicine services. CIS remains at the forefront of technology, providing the highest-quality, compassionate care. This mission has guided the institute for more than 37 years of excellence. For more information about CIS, call 1-800-425-2565 or visit www.cardio.com.
Our goal at CIS is to provide our patients with the highest quality cardiovascular care in the most professional and efficient manner possible. To put these ideals and principles into action, CIS fosters an environment that contributes to both productivity and job satisfaction. Whether you're an experienced professional or a new graduate, CIS is dedicated to helping you develop and fulfill your career.
CAREER OPPORTUNITIES: http://www.cardio.com/career-opportunities
PHYSICIAN RECRUITMENT: http://www.cardio.com/physician-recruitment
Heartflow is the global leader in AI-driven coronary artery disease (CAD) management, transforming how CAD — the world’s leading cause of death — is diagnosed and treated. Our advanced technology generates personalized, precision 3D heart models from a single CT scan, providing clinicians with the clarity and confidence to deliver earlier, more effective treatments — transforming CAD into a disease that can be managed for life.
Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed coronary CTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRct Analysis and Plaque Analysis — is supported by ACC/AHA guidelines and backed by more than 625 peer-reviewed publications.
With over 650,000 patients treated, more than 1,800 leading institutions adopting our solution, and 99.5% of U.S. lives covered — Heartflow is redefining the standard of coronary care. We're a global company, with employees across the United States, Europe and Japan. Our headquarters are in San Francisco, California, with additional offices in California, Texas, the UK and Japan.
We believe CAD shouldn’t be a silent threat. We’re changing the story of CAD by making it screenable, diagnosable, and manageable — empowering clinicians to save lives and giving patients more time for what matters most.